Trial Profile
Phase II, Multicenter, Open-label Dose Finding Study of NGM-282 in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs Aldafermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 29 Aug 2020 Results of pooled analysis assessing plasma levels of PRO-C3X by using data from two phase II studies presented at The International Liver Congress 2020
- 25 Feb 2019 Results (n=43) evaluating efficacy of NGM282 in patients with biopsy-confirmed Nonalcoholic Steatohepatitis published in the Hepatology
- 07 Dec 2018 New trial record